Intellia Therapeutics Announces That Data From The Global Phase 3 HAELO Clinical Trial Of Lonvo-Z In Hereditary Angioedema Will Be Presented At The European Academy Of Allergy & Clinical Immunology Annual Congress 2026

Intellia will also have a poster presentation detailing the burdens experienced by HAE patients living outside the United States.

Late-Breaking Oral Presentation Details:

• Title: HAELO, a Phase 3, Global, Randomised, Double-Blind, Placebo-Controlled Study of Lonvoguran Ziclumeran, a CRISPR-Based Gene Editing Therapy, in Patients with Hereditary Angioedema
  
  Session: Immune deficiencies and autoimmunity
  
  Data and Time: Saturday, June 13, 2026, from 8:45 – 9:45 a.m. TRT
  
  Presentation Number: 100217
  
  Presenter: Danny Cohn, M.D., Ph.D., Internist, Department of Vascular Medicine, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Center, University of Amsterdam

Poster Presentation Details:

• Title: Barriers to Normalization with Existing Treatments Among People Living with Hereditary Angioedema in Europe
  
  Session: Immune deficiencies and autoimmunity 02
  
  Data and Time: Friday, June 12, 2026, from 12:00 – 1:00 p.m. TRT
  
  Poster Number: D1.336
  
  Presenter: Henriette Farkas, M.D., Ph.D., Professor of Allergy and Clinical Immunology Director of the Hungarian Angioedema Center of Reference and Excellence, Department of Internal Medicine and Hematology, Semmelweis University